Company: PRTA
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001559053-25-000009
Chunk: 4

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-02-27
Form: 10-K
Item: Item 10
Chunk 4
---
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Except for the information about our executive officers, Code of Conduct, and Insider Trading Compliance Policy shown below, the information appearing in our Proxy Statement under the following headings is incorporated herein by reference:

•Proposal No. 1 - Election of Directors

•Corporate Governance and Board Matters

•Delinquent Section 16(a) Reports

Information about Our Executive Officers

Following is certain information regarding our executive officers.

NameAgePosition(s)SinceGene G. Kinney56President and Chief Executive Officer, Director2016David A. Ford56Chief People Officer2024Carol D. Karp72Chief Regulatory Officer2016Michael J. Malecek59Chief Legal Officer and Company Secretary2019Tran B. Nguyen51Chief Financial Officer2013Chief Strategy Officer2021Brandon S. Smith 50Chief Operating Officer2021Chad J. Swanson53Chief Development Officer2024Karin L. Walker61Chief Accounting Officer2013Wagner M. Zago52Chief Scientific Officer2017

Gene G. Kinney, Ph.D., has served as our President and Chief Executive Officer as well as a member of our Board of Directors since 2016. Prior to that, he was our Chief Operating Officer for part of 2016, and prior to that he was our Chief Scientific Officer and Head of Research and Development from 2012 to 2016. From 2009 to 2012, Dr. Kinney held various positions with Elan Pharmaceuticals, Inc.: Vice President, Pharmacology (from 2009 to 2011) and Senior Vice President of Pharmacological Sciences (from 2011 to 2012); and while in those positions, he also served as Head of Nonclinical Research for Janssen Alzheimer Immunotherapy R&D. From 2001 to 2009, Dr. Kinney was Senior Director, Head of Central Pharmacology and acting lead for Bioanalytics & Pathology at the Merck Research Laboratories, where he contributed to the strategic direction and oversight of drug discovery activities and led a number of non-clinical discovery and clinical development programs targeted for the treatment of neurodegenerative and psychiatric conditions. Dr. Kinney also held positions at Bristol Myers Squibb and was an Assistant Professor at the Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences. He earned his BA from Bloomsburg University and his MA and PhD from Florida Atlantic University.

David